A development is carried out of biomarkers for the diagnosis and disease state diagnosis of interstitial pneumonia in general or particularly diffuse alveolar damage (DAD), and for the differential diagnosis of other interstitial pneumonias, e.g., organizing pneumonia (OP), and DAD having different treatment responsiveness. Provided is a method for detecting diffuse alveolar damage, comprising measuring the expression in a sample from a subject for at least one protein selected from the group consisting of stratifin, NPS-PLA2, cystatin F, IL-1Ra, netrin-1, and troponin T. Provided is a method for detecting interstitial pneumonia in general (diffuse alveolar damage and other interstitial pneumonias), comprising measuring the expression in a sample from a subject for at least one protein selected from the group consisting of stratifin, kallistatin, NPS-PLA2, PARC (CCL18), LD78-beta, Apo-Al, PAPP-A (pappalysin), complement C3b, and carbonic anhydrase 6.
PROTEIN DIAGNOSTIC BIOMARKERS FOR INTERSTITIAL PNEUMONIA